Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*
Open Access
- 1 March 2015
- journal article
- research article
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 14 (3) , 544-555
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (U01 NS082137, P42 ES004696-5897, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, P50 NS062684-6221, R01 NS065070, P50 AG005131, P50 AG003156-30, R21 NS085425, P30 ES007033)
This publication has 59 references indexed in Scilit:
- Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer’s DiseaseMediators of Inflammation, 2013
- DJ-1 isoforms in whole blood as potential biomarkers of Parkinson diseaseScientific Reports, 2012
- Tissue inhibitor of metalloproteinases-1 protects human neurons from staurosporine and HIV-1-induced apoptosis: mechanisms and relevance to HIV-1-associated dementiaCell Death & Disease, 2012
- Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease PathogenesisThe American Journal of Pathology, 2011
- A targeted proteomics–based pipeline for verification of biomarkers in plasmaNature Biotechnology, 2011
- Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System AtrophyThe American Journal of Pathology, 2011
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionAnnals of Neurology, 2010
- The 28‐amino acid form of an APLP1‐derived Aβ‐like peptide is a surrogate marker for Aβ42 production in the central nervous systemEMBO Molecular Medicine, 2009
- Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasmaNature Biotechnology, 2009
- Glycoproteomics in neurodegenerative diseasesMass Spectrometry Reviews, 2009